B8FK.XETRA Biofrontera AG

Healthcare Drug Manufacturers - Specialty & Generic XETRA Stock Exchange
3.00 EUR
Close of Nov 6, 2026
2.21 5.10
Market cap
EUR 18.2M
P/E
-
P/B
0.91x
ROE
54.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is B8FK.XETRA undervalued?

Graham number

The Graham number of Biofrontera AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biofrontera AG fundamental analysis

No fundamental analysis for Biofrontera AG yet.

Biofrontera AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also provides RhodoLED XL lamp for the tr…

Full company profile